Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.62 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | EP300 | Q09472 | 2/20 | 0.56 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12371424 | 0.88 | TSHR (0.59) | CYP2C9CYP2C19TSHRKMT2AMEN1 | |
| SCHEMBL8482771 | 0.88 | TSHR (0.59) | CYP2C9CYP2C19TSHRKMT2AMEN1 | |
| SCHEMBL12371419 | 0.83 | HCRTR1 (0.50) | CYP2C9CYP2C19TSHRHCRTR1HCRTR2 | |
| SCHEMBL8470652 | 0.83 | HCRTR1 (0.50) | CYP2C9CYP2C19TSHRHCRTR1HCRTR2 | |
| SCHEMBL12371460 | 0.78 | LMNA (0.48) | CYP2C9CYP2C19TSHRKMT2AMEN1 | |
| SCHEMBL2707022 | 0.77 | HCRTR1 (1.00) | TSHRHCRTR1HCRTR2ALDH1A1MAPK1 | |
| SCHEMBL12101312 | 0.76 | TSHR (0.47) | CYP2C9CYP2C19TSHRKMT2AMEN1 | |
| SCHEMBL8128442 | 0.76 | NPC1 (0.70) | TSHRKMT2AMEN1TDP1ALDH1A1 | |
| SCHEMBL15436018 | 0.73 | F10 (0.48) | TSHRHCRTR1HCRTR2KMT2AMEN1 | |
| SCHEMBL12371451 | 0.73 | F10 (0.48) | TSHRHCRTR1HCRTR2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003639-B2 | Substituted prolinamides, the preparation thereof and the use thereof as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-23 | — | — | US | disclosed |
| US-8003639-B2 | Substituted prolinamides, the preparation thereof and the use thereof as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-23 | — | — | US | disclosed |
| US-20090048231-A1 | SUBSTITUTED PROLINAMIDES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | US | disclosed |
| US-20090048231-A1 | SUBSTITUTED PROLINAMIDES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048231-A1 | SUBSTITUTED PROLINAMIDES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | PREP, P4HA1, PPID | CYP2C9 145/4885CYP2C19 231/4885TSHR 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.